本帖最后由 maicon08 于 2023-4-28 15:12 编辑 - W* O; }# b9 m
& b% g; \8 }4 Q* [) x一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。+ G* z- x |( b1 j/ N% h, W, |8 N
9 \% ^) W1 T- Y( m+ dhttps://www.163.com/dy/article/I3BTTPRD053438SI.html
7 Z* `. `. @; Z! B" ~* L% X+ L! G [. R4 L( y
. n! K+ Y3 P' q
在研疗法-免疫治疗5 b6 j Y( q, Z# b1 d+ C7 Q
Developmental Therapeutics—Immunotherapy
+ U j6 t9 c! {% I8 |3 h# _
* l$ L8 O9 D6 v- z* ?摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
# L# ]; O6 H! z# f% \
在研疗法-分子靶向药物和肿瘤生物学
" \0 I) U! y; u" ]% D# I I Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology % p$ V+ ~2 l1 C" G- r7 v; h% u
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
" l4 R2 K% {& C( V/ j
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院
3 `& d: g1 z/ O1 Z
胃肠道肿瘤-结直肠癌和肛门癌5 S, N1 a1 E" k5 d( y( ^6 P g, r
Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院
X! v+ X- u& T# o
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
. r0 K2 i, e, X+ o5 ]% b; O4 p摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 . f+ f: E4 o. A: }$ p
妇科肿瘤 Gynecologic Cancer 7 L$ J5 @/ p$ j9 u8 E) i) i
摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院
/ \( f% _7 Y% f! A
头颈肿瘤
4 h- c$ I8 B" U6 C; v Head and Neck Cancer
9 i( H% e9 t& x1 u+ c" n' J摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
9 T' z4 X8 j& ~" e
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 * H2 c1 d, n2 `+ ]7 o4 }
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心
: t' _7 U I4 F5 x4 ~) X! k
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
1 ^3 k, [* q2 \9 V+ O摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心 2 |7 [1 e! G% X9 }% }
血液系统恶性肿瘤-浆细胞疾病/ h8 O; d1 E; c2 B
Hematologic Malignancies—Plasma Cell Dyscrasia ' |; F# ?+ _2 G# U1 U3 b% m3 s n
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 0 O: S3 q2 Q, H& w" K, p
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
0 x9 I% `% y; E Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
# w c3 l8 p; S: R" n: E2 A摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 * l: W) ^( a6 L9 f
肺癌-转移性非小细胞肺癌
3 }0 T2 R* ^0 I1 Z4 O, d Lung Cancer—Non-Small Cell Metastatic
1 K' o M# T* M摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
! H7 K4 {$ p$ E7 f* x9 |! z
% d' ?7 w+ ~" \6 K
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
, X- O. i3 u% S4 H% n3 y
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 ! i3 b$ ]2 G& d- q- k, H9 Q9 U
黑色素瘤/皮肤癌
; G2 T1 H& c' } s Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院
$ R$ U- v% k+ S! M6 o1 v% {5 }" U* w% v* y
快速摘要报告) r% R7 ^' @. k% U2 K7 F8 h4 Z$ u" [
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心 ; C0 I4 T9 f" F9 Q6 s& s5 t
临床科学研讨会2 L X! k& ~+ ]$ n
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院 7 P8 m6 _/ Z0 m
* y; P4 Z6 L* i8 A, u* u6 Z7 _; p' f7 D# w | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
